Idorsia Ltd (IDIA) - Total Liabilities
Based on the latest financial reports, Idorsia Ltd (IDIA) has total liabilities worth CHF1.59 Billion CHF (≈ $2.01 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Idorsia Ltd generate cash to assess how effectively this company generates cash.
Idorsia Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. Check IDIA financial resilience to evaluate the company's liquid asset resilience ratio.
Idorsia Ltd Competitors by Total Liabilities
The table below lists competitors of Idorsia Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sky Gold Limited
NSE:SKYGOLD
|
India | Rs9.05 Billion |
|
Suzhou Alton Electrical & Mechanical Industry Co. Ltd.
SHE:301187
|
China | CN¥2.35 Billion |
|
indie Semiconductor Inc
NASDAQ:INDI
|
USA | $462.15 Million |
|
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
|
China | CN¥729.22 Million |
|
Zehnder
SW:ZEHN
|
Switzerland | CHF189.35 Million |
|
Hefei Fengle Seed Co Ltd
SHE:000713
|
China | CN¥1.54 Billion |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
Brazil | R$1.79 Billion |
|
Contec Medical Systems Co Ltd
SHE:300869
|
China | CN¥1.02 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Idorsia Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Idorsia Ltd (2016–2024)
The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF1.72 Billion ≈ $2.17 Billion |
+16.98% |
| 2023-12-31 | CHF1.47 Billion ≈ $1.86 Billion |
-6.16% |
| 2022-12-31 | CHF1.57 Billion ≈ $1.98 Billion |
+13.52% |
| 2021-12-31 | CHF1.38 Billion ≈ $1.74 Billion |
+62.23% |
| 2020-12-31 | CHF849.88 Million ≈ $1.07 Billion |
+1.19% |
| 2019-12-31 | CHF839.85 Million ≈ $1.06 Billion |
+12.11% |
| 2018-12-31 | CHF749.14 Million ≈ $947.12 Million |
+35.62% |
| 2017-12-31 | CHF552.37 Million ≈ $698.34 Million |
+35.67% |
| 2016-12-31 | CHF407.15 Million ≈ $514.75 Million |
-- |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more